Avian Flu Collaborations: Aventis, Chiron To Produce Vaccine For NIH Clinical Trials
This article was originally published in The Pink Sheet Daily
Executive Summary
Each company will manufacture 8,000 doses of the avian strain under contracts with the National Institutes of Health. Aventis will perform stability testing to see if its vaccine is suitable for stockpiling.
You may also be interested in...
Flu Pandemic Plan: Financial Incentives To Increase Manufacturing Capacity
HHS plans to increase its demand for influenza vaccine to strengthen the vaccine delivery system and expand manufacturing capacity, a draft document states. Use of adjuvants could expand the vaccine supply, HHS suggests.
Flu Pandemic Plan: Financial Incentives To Increase Manufacturing Capacity
HHS plans to increase its demand for influenza vaccine to strengthen the vaccine delivery system and expand manufacturing capacity, a draft document states. Use of adjuvants could expand the vaccine supply, HHS suggests.
Chiron Will Produce Investigational Avian Flu Vaccine For NIH Clinical Trials
The National Institute of Allergy & Infectious Diseases will conduct safety and immunogenicity studies of the H9N2-based vaccine under an IND. Chiron will produce up to 40,000 doses for testing.